BCR and acute lymphoblastic leukemia: Although dasatinib shows promising early preclinical effects for the treatment of pre-BCR+/E2A-PBX1+ ALL, its ability to target a broad spectrum of different kinases might contribute to the onset of secondary drug resistance.